As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstream, their side-effect profile raises new challenges. In 2011, the Food and Drug Administration approved the first checkpoint inhibitor for the treatment of advanced melanoma, and since then, checkpoint inhibitors have demonstrated efficacy in many…[Read more]

In the last few decades, many efforts have been made to make poly(3-hydroxybutyrate) (PHB) and its copolymers more suitable for industrial production and large-scale use. Plasticization, especially using biodegradable oligomeric plasticizers, has been one of the strategies for this purpose. However, PHB and its copolymers generally present low…[Read more]

3% silane, 2.50% TiO2, and 15.48% polymer concentrations. With a PVDF-TiO2 composite membrane for MD application, the effect of TiO2 was dependent upon silane concentration. Increasing silane concentration improved membrane hydrophobicity and ammonium rejection. RSM analysis was found to bea useful way to explore optimum fabricating conditions of…[Read more]

3% silane, 2.50% TiO2, and 15.48% polymer concentrations. With a PVDF-TiO2 composite membrane for MD application, the effect of TiO2 was dependent upon silane concentration. Increasing silane concentration improved membrane hydrophobicity and ammonium rejection. RSM analysis was found to bea useful way to explore optimum fabricating conditions of…[Read more]

Pathogenic variants in TPM2 have been associated with a variable clinical spectrum, including congenital myopathies and distal arthrogryposis, all but one with dominant inheritance. We report the second case of recessively inherited TPM2-related Escobar variant of multiple pterygium syndrome and congenital myopathy in a patient from a…[Read more]